Coya Therapeutics reports Q3 net loss of $2.1M; IND accepted for COYA 302 in ALS

Coya Therapeutics, Inc.

2025-Q3 EPS reported -$0.93 vs consensus -$0.28 ▼ miss (-233.6%)

Net loss of $2.1M for Q3 2025 improved from $4.0M loss in Q3 2024; cash and equivalents at $28.1M.
FDA accepted IND for COYA 302 in ALS; ALSTARS Phase 2 trial launched with up to 25 sites.
Closed $23.0M upsized public offering; cash runway extended into second half of 2027.
Received $4.2M milestone from Dr. Reddy's for IND approval; additional $4.2M due on first dosing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.